

Liver cancer-resisting monoclonal antibody HAb25 and its single stranded antibody and bifunctional antibody

Patent number: CN1241574
Publication date: 2000-01-19
Inventor: LIU YANFANG (CN)
Applicant: NO 4 MILITARY MEDICAL UNIV PLA (CN)
Classification:
- international: **C07K16/30; C12N5/20; C07K16/18; C12N5/20; (IPC1-7): C07K16/30; C12N5/20**
- european:
Application number: CN19981012905 19980702
Priority number(s): CN19981012905 19980702

Report a data error here

Abstract of CN1241574

The present invention relates to gene engineering technology. Technologically, the present invention features that hybrid tumor technology is first utilized to prepare mouse-originating monoclonal antibody HAb25 with specific combination activity to human liver cancer cells; and HAb25 is re-constructed through gene engineering process into liver cancer resisting single stranded antibody scFv25 and liver cancer resisting bifunctional antibody pBV220-scFv25-PE40 and pGEX4T-1-scFv25-TNF α . The liver cancer resisting gene engineering antibody has the features of small molecular weight, strong penetration capacity, high molecule stability, low toxic side effect, high efficiency, easy mass production, etc., and thus has great latent clinical application capability.

~~~~~  
Data supplied from the **esp@cenet** database - Worldwide